Dossier
insulin pricing
Coverage of insulin pricing in the Nexus archive.
- STAT+: Is there a pharma mega-merger in the making?
The article discusses the FDA's upcoming decision on Moderna's mRNA flu shot, a renewed debate over 340B rebates, and legal challenges regarding Lilly's insulin pricing. It highlights key developments in the biotech and pharmaceutical sectors.
- $35 insulin deal has 60 votes in Senate
A bipartisan Senate deal to cap insulin prices at $35 for Americans with employer-sponsored or private insurance has secured 60 votes, including support from 47 Democrats and 13 Republicans. Public polling indicates 68% support for the measure, with potential political benefits for both parties.